Assembly Biosciences, Inc. – NASDAQ:ASMB
Assembly Biosciences stock price today
$25.2
+10.04
+66.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Assembly Biosciences stock price monthly change
+2.43%
month
Assembly Biosciences stock price quarterly change
+2.43%
quarter
Assembly Biosciences stock price yearly change
+1762.41%
year
Assembly Biosciences key metrics
Market Cap | 95.36M |
Enterprise value | N/A |
P/E | -0.44 |
EV/Sales | N/A |
EV/EBITDA | 0.05 |
Price/Sales | N/A |
Price/Book | 0.49 |
PEG ratio | -0.01 |
EPS | -10.83 |
Revenue | N/A |
EBITDA | -55.57M |
Income | -51.35M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAssembly Biosciences stock price history
Assembly Biosciences stock forecast
Assembly Biosciences financial statements
| Jun 2023 | 0 | -16.89M | |
|---|---|---|---|
| Sep 2023 | 0 | -14.42M | |
| Dec 2023 | 7.16M | -10.96M | -153.04% |
| Mar 2024 | 5.78M | -9.07M | -156.91% |
| 2025 | 14.52M | -54.80M | -377.41% |
|---|---|---|---|
| 2026 | 66.07M | -64.56M | -97.7% |
| 2027 | 218M | -75.80M | -34.77% |
| 2028 | 1.93M | -77.40M | -3998.31% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 66577000 | 11.62M | 17.47% |
|---|---|---|---|
| Sep 2023 | 51629000 | 9.91M | 19.2% |
| Dec 2023 | 137469000 | 96.37M | 70.1% |
| Mar 2024 | 119883000 | 87.28M | 72.81% |
| Jun 2023 | -13.62M | -8.36M | 134K |
|---|---|---|---|
| Sep 2023 | -13.84M | 18.88M | 0 |
| Dec 2023 | 73.64M | -89.65M | 9.19M |
| Mar 2024 | -18.36M | 17.27M | 0 |
Assembly Biosciences alternative data
| Sep 2023 | 70 |
|---|---|
| Oct 2023 | 70 |
| Nov 2023 | 70 |
| Dec 2023 | 68 |
| Jan 2024 | 68 |
| Feb 2024 | 68 |
| Mar 2024 | 68 |
| Apr 2024 | 68 |
| May 2024 | 65 |
| Jun 2024 | 65 |
| Jul 2024 | 65 |
Assembly Biosciences other data
8.18%
-21.11%
of ASMB is owned by hedge funds
19
-20
3.96M
-10.23M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 645080 | 0 |
| Mar 2024 | 0 | 392 |
| Apr 2024 | 0 | 4695 |
| May 2024 | 0 | 2862 |
| Jun 2024 | 359000 | 0 |
| Jul 2024 | 9000 | 0 |
| Aug 2024 | 0 | 1766 |
| Oct 2024 | 10000 | 354 |
| Nov 2024 | 25000 | 40 |
| Dec 2024 | 940499 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GILEAD SCIENCES, INC. 10 percent owner | Common Stock | 940,499 | $21.37 | $20,098,464 | ||
Purchase | SCHORNSTEIN ALEXANDER 10 percent owner | Common Stock | 5,000 | $14.85 | $74,250 | ||
Purchase | SCHORNSTEIN ALEXANDER 10 percent owner | Common Stock | 2,976 | $15 | $44,640 | ||
Purchase | SCHORNSTEIN ALEXANDER 10 percent owner | Common Stock | 17,024 | $14.87 | $253,113 | ||
Sale | WHITE NICOLE S officer: Chief Manufacturing Of.. | Common Stock | 40 | $16.29 | $652 | ||
Purchase | SCHORNSTEIN ALEXANDER 10 percent owner | Common Stock | 10,000 | $14.58 | $145,800 | ||
Sale | WHITE NICOLE S officer: Chief Manufacturing Of.. | Common Stock | 157 | $14.81 | $2,325 | ||
Sale | OKAZAKI JASON A director, officer.. | Common Stock | 197 | $14.81 | $2,918 | ||
Sale | WHITE NICOLE S officer: Chief Manufacturing Of.. | Common Stock | 785 | $14.23 | $11,173 | ||
Sale | OKAZAKI JASON A director, officer.. | Common Stock | 981 | $14.23 | $13,963 |
| Patent |
|---|
Application Filling date: 22 May 2020 Issue date: 4 Aug 2022 |
Application Filling date: 5 Sep 2019 Issue date: 17 Mar 2022 |
Application Filling date: 14 Jan 2021 Issue date: 27 Jan 2022 |
Application Filling date: 14 Jan 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 13 Mar 2018 Issue date: 22 Jun 2021 |
Grant Utility: Hepatitis B core protein modulators Filling date: 14 Sep 2017 Issue date: 27 Apr 2021 |
Grant Utility: Hepatitis B core protein modulators Filling date: 30 May 2019 Issue date: 6 Apr 2021 |
Grant Filling date: 27 Apr 2018 Issue date: 16 Mar 2021 |
Application Filling date: 28 Aug 2020 Issue date: 4 Mar 2021 |
Grant Utility: Hepatitis B core protein modulators Filling date: 15 Sep 2016 Issue date: 8 Sep 2020 |
| Insider | Compensation |
|---|---|
Dr. John G. McHutchison A.O., FRACP, M.D. (1957) Chief Executive Officer, Pres & Director | $1,440,000 |
| Mr. Jason A. Okazaki (1976) Chief Operating Officer | $703,270 |
| Dr. William E. Delaney IV, Ph.D. (1972) Chief Scientific Officer | $450,870 |
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Hookipa: Speculative Biotech With Key Catalysts In 2022
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna
Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications
Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment
-
What's the price of Assembly Biosciences stock today?
One share of Assembly Biosciences stock can currently be purchased for approximately $25.2.
-
When is Assembly Biosciences's next earnings date?
Unfortunately, Assembly Biosciences's (ASMB) next earnings date is currently unknown.
-
Does Assembly Biosciences pay dividends?
No, Assembly Biosciences does not pay dividends.
-
How much money does Assembly Biosciences make?
Assembly Biosciences has a market capitalization of 95.36M.
-
What is Assembly Biosciences's stock symbol?
Assembly Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "ASMB".
-
What is Assembly Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Assembly Biosciences?
Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Assembly Biosciences's key executives?
Assembly Biosciences's management team includes the following people:
- Dr. John G. McHutchison A.O., FRACP, M.D. Chief Executive Officer, Pres & Director(age: 68, pay: $1,440,000)
- Mr. Jason A. Okazaki Chief Operating Officer(age: 49, pay: $703,270)
- Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer(age: 53, pay: $450,870)
-
How many employees does Assembly Biosciences have?
As Jul 2024, Assembly Biosciences employs 65 workers, which is 4% less then previous quarter.
-
When Assembly Biosciences went public?
Assembly Biosciences, Inc. is publicly traded company for more then 14 years since IPO on 17 Dec 2010.
-
What is Assembly Biosciences's official website?
The official website for Assembly Biosciences is assemblybio.com.
-
Where are Assembly Biosciences's headquarters?
Assembly Biosciences is headquartered at 331 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Assembly Biosciences?
Assembly Biosciences's mailing address is 331 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at 833 509 4583.
Assembly Biosciences company profile:
Assembly Biosciences, Inc.
assemblybio.comExchange:
NASDAQ
Full time employees:
65
Industry:
Biotechnology
Sector:
Healthcare
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
331 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001426800
ISIN: US0453962070
CUSIP: 045396108
